134 related articles for article (PubMed ID: 32495158)
1. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
[TBL] [Abstract][Full Text] [Related]
2. Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma.
Chrabańska M; Szweda-Gandor N; Rynkiewicz M; Hraboš D; Drozdzowska B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612724
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI
Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
Chang K; Qu Y; Dai B; Zhao JY; Gan H; Shi G; Zhu Y; Shen Y; Zhu Y; Zhang H; Ye D
Sci Rep; 2017 May; 7(1):2074. PubMed ID: 28522811
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective.
Lavacchi D; Pellegrini E; Palmieri VE; Doni L; Mela MM; Di Maida F; Amedei A; Pillozzi S; Carini M; Antonuzzo L
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630154
[TBL] [Abstract][Full Text] [Related]
6. Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β.
Hirayama A; Tanaka K; Tsutsumi H; Nakanishi T; Yamashita S; Mizusaki S; Ishii Y; Ota K; Yoneshima Y; Iwama E; Okamoto I
Front Immunol; 2023; 14():1192861. PubMed ID: 37441079
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
Chiang SF; Huang CY; Ke TW; Chen TW; Lan YC; You YS; Chen WT; Chao KSC
Cancer Immunol Immunother; 2019 Feb; 68(2):283-296. PubMed ID: 30448924
[TBL] [Abstract][Full Text] [Related]
8. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Yan Y; Zheng L; Du Q; Yan B; Geller DA
Cancer Immunol Immunother; 2020 Sep; 69(9):1891-1903. PubMed ID: 32377817
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of Immune checkpoint PD-L1 in Colon cancer cell lines and activation of T cells by Leuconostoc mesenteroides.
Altves S; Guclu E; Yetisgin E; Bilecen K; Vural H
World J Microbiol Biotechnol; 2024 May; 40(7):204. PubMed ID: 38755413
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms regulating PD-L1 expression on tumor and immune cells.
Chen S; Crabill GA; Pritchard TS; McMiller TL; Wei P; Pardoll DM; Pan F; Topalian SL
J Immunother Cancer; 2019 Nov; 7(1):305. PubMed ID: 31730010
[TBL] [Abstract][Full Text] [Related]
11. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.
Ascierto ML; McMiller TL; Berger AE; Danilova L; Anders RA; Netto GJ; Xu H; Pritchard TS; Fan J; Cheadle C; Cope L; Drake CG; Pardoll DM; Taube JM; Topalian SL
Cancer Immunol Res; 2016 Sep; 4(9):726-33. PubMed ID: 27491898
[TBL] [Abstract][Full Text] [Related]
12. Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas.
Wei S; Krause HB; Geynisman DM; Elliott A; Kutikov A; Uzzo RG; Pei J; Barata P; Carneiro B; Heath E; Ryan C; Farrell A; Nabhan C; Ali-Fehmi R; Naqash AR; Argani P; McKay RR
Mod Pathol; 2024 Feb; 37(2):100404. PubMed ID: 38104891
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of the canonical signaling pathway of interferon-gamma is associated with glioblastoma progression.
Zamora-Salas SX; Macías-Silva M; Tecalco-Cruz AC
Mol Biol Rep; 2024 Jan; 51(1):64. PubMed ID: 38170343
[TBL] [Abstract][Full Text] [Related]
14. IFN-
Jia H; Xie X; Wang L; Wang L; Che F
Comput Intell Neurosci; 2022; 2022():5492602. PubMed ID: 35814563
[TBL] [Abstract][Full Text] [Related]
15. Free-Fatty Acid Receptor-4 (FFA4/GPR120) differentially regulates migration, invasion, proliferation and tumor growth of papillary renal cell carcinoma cells.
Karmokar PF; Moniri NH
Biochem Pharmacol; 2023 Jul; 213():115590. PubMed ID: 37201877
[TBL] [Abstract][Full Text] [Related]
16. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
Jikuya R; Kishida T; Sakaguchi M; Yokose T; Yasui M; Hashizume A; Tatenuma T; Mizuno N; Muraoka K; Umemoto S; Kawai M; Yoshihara M; Nakamura Y; Miyagi Y; Sasada T
Cancer Immunol Immunother; 2020 Oct; 69(10):2041-2051. PubMed ID: 32424467
[TBL] [Abstract][Full Text] [Related]
17. Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues.
Yoo SH; Yun J; Keam B; Hong SP; Ock CY; Koh J; Kim S; Jeon YK; Jung KC; Kim M; Kim TM; Kim DW; Kim JI; Heo DS
Cancer Immunol Immunother; 2021 Jun; 70(6):1755-1769. PubMed ID: 33389015
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
Naffrichoux J; Poupin P; Pouillot W; Linassier C; Rioux-Leclercq N; De Vries-Brilland M; Mourey L; Laguerre B; Oudard S; Gross-Goupil M; Mousset C; Gravis G; Rolland F; Moise L; Emambux S; Vassal C; Zanetta S; Penel N; Albiges L; Fromont G; Cancel M
Eur J Cancer; 2024 May; 205():114121. PubMed ID: 38749111
[TBL] [Abstract][Full Text] [Related]
19. Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.
Horowitch B; Lee DY; Ding M; Martinez-Morilla S; Aung TN; Ouerghi F; Wang X; Wei W; Damsky W; Sznol M; Kluger H; Rimm DL; Ishizuka JJ
Clin Cancer Res; 2023 Aug; 29(15):2908-2918. PubMed ID: 37233452
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma.
Stühler V; Alemi B; Rausch S; Stenzl A; Schwab M; Schaeffeler E; Bedke J
World J Urol; 2024 Jan; 42(1):53. PubMed ID: 38244072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]